Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine

We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was init...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2021-09, Vol.28 (5), p.285-288
Hauptverfasser: Torroba Sanz, Beatriz, Mendez Martínez, Elena, Cacho Asenjo, Elena, Aquerreta Gonzalez, Irene
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 288
container_issue 5
container_start_page 285
container_title European journal of hospital pharmacy. Science and practice
container_volume 28
creator Torroba Sanz, Beatriz
Mendez Martínez, Elena
Cacho Asenjo, Elena
Aquerreta Gonzalez, Irene
description We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.
doi_str_mv 10.1136/ejhpharm-2019-002149
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564131918</sourcerecordid><originalsourceid>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</originalsourceid><addsrcrecordid>eNqNkU1vFSEUhomxsc21_8AYEjftYiwMzDBsTEytH0mTGqtrwsC5HW4GGGHG5m795VJve_1YGFecwPO-nHNehJ5R8pJS1p7BZpgGnXxVEyorQmrK5SN0VBMuKilb_nhfN-0hOs7Z9aRhrJOcySfokHFet7xjR-j7R0heBwgzThD0iDN8XWDUUAoTg9Vpi-eIbVpuCqDN7GLAt24eMMTsQpwGNzqNdbA4b_MM3plS-GmOPuOTN58urq9Py0WwKXrALtjFgMX9FpdfZqcnF-ApOljrMcPx_blCX95efD5_X11evftw_vqy6hsq5qq2NeutXgspe7Y2DARQIwz0tm4N6UVHedsI1nWy0ZZw0mqoidFUUNYRbSRboVc732npPVhTZk56VFNyvkyponbqz5fgBnUTv6mOEyYEKwYn9wYplvbzrLzLBsax7C8uWdVNyymjknYFffEXuolLKvv9SbGWSlKOFeI7yqSYc4L1vhlK1F3O6iFndZez2uVcZM9_H2Qveki1AGc7oPeb_7UkvxT7Vv8p-QEdrses</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563619056</pqid></control><display><type>article</type><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</creator><creatorcontrib>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</creatorcontrib><description>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-002149</identifier><identifier>PMID: 34426483</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>adverse effects ; Allergies ; Antimicrobial agents ; Blood diseases ; Case Report ; chronic renal failure ; clinical pharmacy ; Creatinine ; Delirium ; dermatology ; Drug dosages ; Drug Hypersensitivity Syndrome - diagnosis ; Drug Hypersensitivity Syndrome - drug therapy ; Drug Hypersensitivity Syndrome - etiology ; Drug interactions ; Drug withdrawal ; Eosinophilia - chemically induced ; Eosinophilia - complications ; Eosinophilia - diagnosis ; Extracorporeal membrane oxygenation ; Hematology ; Hepatitis ; Humans ; intensive &amp; critical care ; Kidney ; Male ; Mortality ; Myocarditis ; Pathophysiology ; Patients ; Psychotropic drugs ; Quetiapine Fumarate - adverse effects ; Side effects ; Skin ; Steroids ; Ventilators</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.285-288</ispartof><rights>European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</citedby><cites>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</cites><orcidid>0000-0003-2574-4076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403773/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403773/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34426483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torroba Sanz, Beatriz</creatorcontrib><creatorcontrib>Mendez Martínez, Elena</creatorcontrib><creatorcontrib>Cacho Asenjo, Elena</creatorcontrib><creatorcontrib>Aquerreta Gonzalez, Irene</creatorcontrib><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</description><subject>adverse effects</subject><subject>Allergies</subject><subject>Antimicrobial agents</subject><subject>Blood diseases</subject><subject>Case Report</subject><subject>chronic renal failure</subject><subject>clinical pharmacy</subject><subject>Creatinine</subject><subject>Delirium</subject><subject>dermatology</subject><subject>Drug dosages</subject><subject>Drug Hypersensitivity Syndrome - diagnosis</subject><subject>Drug Hypersensitivity Syndrome - drug therapy</subject><subject>Drug Hypersensitivity Syndrome - etiology</subject><subject>Drug interactions</subject><subject>Drug withdrawal</subject><subject>Eosinophilia - chemically induced</subject><subject>Eosinophilia - complications</subject><subject>Eosinophilia - diagnosis</subject><subject>Extracorporeal membrane oxygenation</subject><subject>Hematology</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>intensive &amp; critical care</subject><subject>Kidney</subject><subject>Male</subject><subject>Mortality</subject><subject>Myocarditis</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Psychotropic drugs</subject><subject>Quetiapine Fumarate - adverse effects</subject><subject>Side effects</subject><subject>Skin</subject><subject>Steroids</subject><subject>Ventilators</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1vFSEUhomxsc21_8AYEjftYiwMzDBsTEytH0mTGqtrwsC5HW4GGGHG5m795VJve_1YGFecwPO-nHNehJ5R8pJS1p7BZpgGnXxVEyorQmrK5SN0VBMuKilb_nhfN-0hOs7Z9aRhrJOcySfokHFet7xjR-j7R0heBwgzThD0iDN8XWDUUAoTg9Vpi-eIbVpuCqDN7GLAt24eMMTsQpwGNzqNdbA4b_MM3plS-GmOPuOTN58urq9Py0WwKXrALtjFgMX9FpdfZqcnF-ApOljrMcPx_blCX95efD5_X11evftw_vqy6hsq5qq2NeutXgspe7Y2DARQIwz0tm4N6UVHedsI1nWy0ZZw0mqoidFUUNYRbSRboVc732npPVhTZk56VFNyvkyponbqz5fgBnUTv6mOEyYEKwYn9wYplvbzrLzLBsax7C8uWdVNyymjknYFffEXuolLKvv9SbGWSlKOFeI7yqSYc4L1vhlK1F3O6iFndZez2uVcZM9_H2Qveki1AGc7oPeb_7UkvxT7Vv8p-QEdrses</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Torroba Sanz, Beatriz</creator><creator>Mendez Martínez, Elena</creator><creator>Cacho Asenjo, Elena</creator><creator>Aquerreta Gonzalez, Irene</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2574-4076</orcidid></search><sort><creationdate>20210901</creationdate><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><author>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse effects</topic><topic>Allergies</topic><topic>Antimicrobial agents</topic><topic>Blood diseases</topic><topic>Case Report</topic><topic>chronic renal failure</topic><topic>clinical pharmacy</topic><topic>Creatinine</topic><topic>Delirium</topic><topic>dermatology</topic><topic>Drug dosages</topic><topic>Drug Hypersensitivity Syndrome - diagnosis</topic><topic>Drug Hypersensitivity Syndrome - drug therapy</topic><topic>Drug Hypersensitivity Syndrome - etiology</topic><topic>Drug interactions</topic><topic>Drug withdrawal</topic><topic>Eosinophilia - chemically induced</topic><topic>Eosinophilia - complications</topic><topic>Eosinophilia - diagnosis</topic><topic>Extracorporeal membrane oxygenation</topic><topic>Hematology</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>intensive &amp; critical care</topic><topic>Kidney</topic><topic>Male</topic><topic>Mortality</topic><topic>Myocarditis</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Psychotropic drugs</topic><topic>Quetiapine Fumarate - adverse effects</topic><topic>Side effects</topic><topic>Skin</topic><topic>Steroids</topic><topic>Ventilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torroba Sanz, Beatriz</creatorcontrib><creatorcontrib>Mendez Martínez, Elena</creatorcontrib><creatorcontrib>Cacho Asenjo, Elena</creatorcontrib><creatorcontrib>Aquerreta Gonzalez, Irene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torroba Sanz, Beatriz</au><au>Mendez Martínez, Elena</au><au>Cacho Asenjo, Elena</au><au>Aquerreta Gonzalez, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>28</volume><issue>5</issue><spage>285</spage><epage>288</epage><pages>285-288</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>34426483</pmid><doi>10.1136/ejhpharm-2019-002149</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-2574-4076</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.285-288
issn 2047-9956
2047-9964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403773
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects adverse effects
Allergies
Antimicrobial agents
Blood diseases
Case Report
chronic renal failure
clinical pharmacy
Creatinine
Delirium
dermatology
Drug dosages
Drug Hypersensitivity Syndrome - diagnosis
Drug Hypersensitivity Syndrome - drug therapy
Drug Hypersensitivity Syndrome - etiology
Drug interactions
Drug withdrawal
Eosinophilia - chemically induced
Eosinophilia - complications
Eosinophilia - diagnosis
Extracorporeal membrane oxygenation
Hematology
Hepatitis
Humans
intensive & critical care
Kidney
Male
Mortality
Myocarditis
Pathophysiology
Patients
Psychotropic drugs
Quetiapine Fumarate - adverse effects
Side effects
Skin
Steroids
Ventilators
title Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T15%3A23%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Permanent%20renal%20sequelae%20secondary%20to%20drug%20reaction%20with%20eosinophilia%20and%20systemic%20symptoms%20(DRESS)%20syndrome%20induced%20by%20quetiapine&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Torroba%20Sanz,%20Beatriz&rft.date=2021-09-01&rft.volume=28&rft.issue=5&rft.spage=285&rft.epage=288&rft.pages=285-288&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-002149&rft_dat=%3Cproquest_pubme%3E2564131918%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563619056&rft_id=info:pmid/34426483&rfr_iscdi=true